샘플 요청 목록

 카트 문의
시장보고서
상품코드
1785858

세계의 블록버스터 종양학 브랜드 시장

Blockbuster Oncology Brands
발행일: | 리서치사: Global Industry Analysts, Inc. | 페이지 정보: 영문 284 Pages | 배송안내 : 1-2일 (영업일 기준)

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계의 블록버스터 종양학 브랜드 시장은 2030년까지 643억 달러에 도달

2024년에 429억 달러로 추정되는 세계의 블록버스터 종양학 브랜드 시장은 2024-2030년의 분석 기간에 CAGR 7.0%로 성장하며, 2030년에는 643억 달러에 달할 것으로 예측됩니다. 이 리포트에서 분석한 부문의 하나인 폐암은 CAGR 7.9%를 기록하며, 분석 기간 종료시에는 327억 달러에 달할 것으로 예측됩니다. 유방암 분야의 성장률은 분석 기간 중 CAGR 6.8%로 추정됩니다.

미국 시장은 추정 117억 달러, 중국은 CAGR 11.1%로 성장 예측

미국의 블록버스터 종양학 브랜드 시장은 2024년에 117억 달러로 추정됩니다. 세계 2위의 경제대국인 중국은 2030년까지 135억 달러의 시장 규모에 달할 것으로 예측되며, 분석 기간인 2024-2030년 CAGR은 11.1%입니다. 기타 주목할 만한 지역별 시장으로는 일본과 캐나다가 있으며, 분석 기간 중 CAGR은 각각 3.4%와 6.8%로 예측됩니다. 유럽에서는 독일이 CAGR 4.6%로 성장할 것으로 예측됩니다.

세계의 블록버스터 종양학 브랜드 시장 - 주요 동향과 촉진요인 정리

블록버스터 종양학 브랜드가 암 치료 시장을 독점하고 있는 이유는 무엇인가?

블록버스터 종양학 브랜드는 환자의 예후를 크게 개선하는 표적화된 매우 효과적인 치료법을 제공함으로써 현대 암 치료의 핵심으로 부상하고 있습니다. 전 세계 암 발병률 증가와 암 치료제 개발에 대한 투자 증가가 맞물리면서 여러 암종에 대해 우수한 효능을 보이는 첨단 치료제에 대한 수요가 증가하고 있습니다. 제약사들은 암 분야를 중요한 치료 영역으로 우선순위를 두고 있으며, 이는 면역관문억제제, 표적치료제, 맞춤의료 접근법 등 획기적인 약물의 도입으로 이어지고 있습니다. 이들 브랜드는 큰 시장 점유율을 차지하고 있을 뿐만 아니라, 암 분야 임상 혁신의 벤치마킹 대상이 되고 있습니다. 블록버스터 종양학 브랜드가 성공할 수 있었던 주요 이유 중 하나는 정밀의료를 활용하는 능력입니다. 암세포와 건강한 세포를 무차별적으로 공격하는 기존 화학요법과 달리 표적치료는 암세포와 관련된 특정 분자 마커나 유전자 마커에 초점을 맞춥니다. 이 접근법은 부작용을 최소화하면서 치료 효과를 극대화할 수 있으며, 종양내과 의사와 환자 모두에게 선호되는 치료법입니다. 의료 서비스 프로바이더들이 개인 맞춤형 치료 계획을 중시함에 따라 이러한 고성능 종양학 브랜드에 대한 수요는 가속화될 것으로 예상되며, 시장에서의 우위는 더욱 강화될 것으로 보입니다.

기술의 발전은 암 치료제 시장을 어떻게 형성하고 있는가?

생명공학 및 유전체 연구의 발전은 블록버스터 종양학 브랜드의 진화에 있으며, 매우 중요한 역할을 하고 있습니다. 차세대 염기서열 분석(NGS)과 바이오마커 기반 의약품 개발은 제약회사들이 개별 암 프로파일에 매우 특화된 치료법을 설계할 수 있게 해줍니다. 이러한 정밀 종양학으로의 전환은 독성 및 치료 저항성을 줄이면서 환자의 예후를 개선하는 표적 치료의 창출로 이어질 것입니다. 또한 AI를 활용한 신약개발은 새로운 암 치료제의 개발 및 시험에 소요되는 시간을 크게 단축하고, 규제 당국의 승인을 받기까지 걸리는 시간을 단축하고 있습니다. 종양학 시장의 또 다른 큰 기술적 변화는 면역치료의 부상입니다. PD-1 억제제나 CTLA-4 억제제와 같은 체크포인트 억제제는 암과 싸우기 위해 신체의 면역체계를 이용함으로써 암 치료를 혁신적으로 변화시켰습니다. 또한 CAR-T 세포 치료는 혈액 악성 종양 치료의 획기적인 접근법으로 주목받고 있습니다. 이러한 발전은 생존율을 향상시킬 뿐만 아니라, 이전에는 선택의 폭이 제한적이었던 환자들의 치료 선택권을 넓혀주고 있습니다. 제약사들이 면역치료와 표적치료제를 통합한 병용요법에 대한 투자를 지속하는 가운데, 블록버스터 종양학 브랜드 시장은 비약적인 성장을 이룰 것으로 보입니다.

블록버스터 종양 브랜드 확장을 주도하는 시장 동향은?

암 치료제 시장은 치료 효과와 환자 중심의 결과가 약가와 채택을 결정하는 가치 기반 치료로의 전환을 목격하고 있습니다. 정부 및 의료 기관은 암 치료제의 비용 효율성을 점점 더 중요시하고 있으며, 제약사는 임상적 가치가 높은 치료법 개발에 집중하고 있습니다. 이러한 추세에 따라 결과 기반 가격 책정 모델과 유효성이 높은 암 치료제의 사용을 장려하는 상환 구조가 확대되고 있습니다. 시장을 형성하는 또 다른 주요 동향은 바이오시밀러의 채택 확대입니다. 히트한 암 치료제의 특허가 만료됨에 따라 바이오시밀러 의약품의 경쟁이 치열해지면서 치료비 인하와 환자 접근성 향상이 기대되고 있습니다. 그러나 바이오시밀러의 도전에도 불구하고 주요 암 치료제 브랜드들은 지속적인 기술 혁신, 수명주기관리 전략, 동반진단 용도를 확대하기 위한 진단 기업과의 전략적 제휴를 통해 시장 우위를 유지하고 있습니다. 또한 원격 환자 모니터링 및 AI 기반 치료 추천을 포함한 디지털 헬스 기술의 발전은 히트한 암 치료제의 효능을 더욱 최적화하고 있습니다.

블록버스터 종양 브랜드 시장의 주요 성장 촉진요인은?

블록버스터 항암제 브랜드 시장의 성장은 전 세계 암 부담 증가, 표적치료제 및 면역치료제의 지속적인 기술 혁신, 획기적인 암 치료제에 대한 규제 당국의 승인 확대 등 여러 요인에 기인합니다. 바이오마커 중심의 의약품 개발이 통합되면서 제약사들은 특정 암종에 맞는 매우 효과적인 치료법을 개발할 수 있게 되었고, 시장의 성장은 더욱 가속화되고 있습니다. 또한 여러 약물이 시너지 효과를 발휘하여 치료 효과를 높이는 병용요법의 등장으로 블록버스터 항암제 브랜드에 대한 수요가 증가하고 있습니다. 또한 환자 개개인에게 가장 적합한 치료법을 찾아주는 동반진단약의 채택이 확대되고 있는 것도 시장 확대에 중요한 역할을 하고 있습니다. 또한 유전체 연구와 AI를 활용한 신약개발의 발전에 힘입어 맞춤형 의료와 정밀 종양학으로의 전환은 이 분야의 지속적인 성장을 보장하고 있습니다. 암 연구개발에 대한 투자가 지속적으로 증가하고 전 세계에서 의료 인프라가 개선됨에 따라 블록버스터 종양학 브랜드 시장은 향후 수년간 강력하고 안정적인 확장을 보일 것으로 예측됩니다.

부문

치료 유형(폐암, 유방암, 다발성골수종, 림프종, 기타 치료 유형), 유통 채널(병원 약국, 소매 약국, 기타 유통 채널)

조사 대상 기업의 예

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • Bayer's Pharmaceuticals
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Leapfrog Bio
  • Pfizer Inc.
  • pharmaand GmbH
  • Vidac Pharma

AI 통합

Global Industry Analysts는 유효한 전문가 컨텐츠와 AI 툴에 의해 시장 정보와 경쟁 정보를 변혁하고 있습니다.

Global Industry Analysts는 LLM나 업계 고유 SLM를 조회하는 일반적인 규범에 따르는 대신에, 비디오 기록, 블로그, 검색 엔진 조사, 방대한 양 기업, 제품/서비스, 시장 데이터 등, 전 세계 전문가로부터 수집한 컨텐츠 리포지토리를 구축했습니다.

관세 영향 계수

Global Industry Analysts는 본사 소재지, 제조거점, 수출입(완제품 및 OEM)을 기준으로 기업의 경쟁력 변화를 예측했습니다. 이러한 복잡하고 다면적인 시장 역학은 수입원가(COGS) 증가, 수익성 하락, 공급망 재편 등 미시적, 거시적 시장 역학 중에서도 특히 경쟁사들에게 영향을 미칠 것으로 예측됩니다.

목차

제1장 조사 방법

제2장 개요

  • 시장 개요
  • 주요 기업
  • 시장 동향과 촉진요인
  • 세계 시장 전망

제3장 시장 분석

  • 미국
  • 캐나다
  • 일본
  • 중국
  • 유럽
  • 프랑스
  • 독일
  • 이탈리아
  • 영국
  • 스페인
  • 러시아
  • 기타 유럽
  • 아시아태평양
  • 호주
  • 인도
  • 한국
  • 기타 아시아태평양
  • 라틴아메리카
  • 아르헨티나
  • 브라질
  • 멕시코
  • 기타 라틴아메리카
  • 중동
  • 이란
  • 이스라엘
  • 사우디아라비아
  • 아랍에미리트
  • 기타 중동
  • 아프리카

제4장 경쟁

KSA 25.08.19

Global Blockbuster Oncology Brands Market to Reach US$64.3 Billion by 2030

The global market for Blockbuster Oncology Brands estimated at US$42.9 Billion in the year 2024, is expected to reach US$64.3 Billion by 2030, growing at a CAGR of 7.0% over the analysis period 2024-2030. Lung Cancer, one of the segments analyzed in the report, is expected to record a 7.9% CAGR and reach US$32.7 Billion by the end of the analysis period. Growth in the Breast Cancer segment is estimated at 6.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.7 Billion While China is Forecast to Grow at 11.1% CAGR

The Blockbuster Oncology Brands market in the U.S. is estimated at US$11.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$13.5 Billion by the year 2030 trailing a CAGR of 11.1% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.4% and 6.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 4.6% CAGR.

Global Blockbuster Oncology Brands Market - Key Trends & Drivers Summarized

Why Are Blockbuster Oncology Brands Dominating the Cancer Treatment Market?

Blockbuster oncology brands have emerged as a cornerstone of modern cancer treatment, offering targeted and highly effective therapies that significantly improve patient outcomes. The rise in global cancer prevalence, coupled with increased investment in oncology drug development, has driven the demand for advanced therapeutics that can address multiple cancer types with superior efficacy. Pharmaceutical giants are prioritizing oncology as a key therapeutic area, leading to the introduction of groundbreaking drugs, including immune checkpoint inhibitors, targeted therapies, and personalized medicine approaches. These brands not only command significant market share but also set the benchmark for clinical innovation in the oncology space. One of the primary reasons for the success of blockbuster oncology brands is their ability to leverage precision medicine. Unlike traditional chemotherapy, which indiscriminately attacks both cancerous and healthy cells, targeted therapies focus on specific molecular and genetic markers associated with cancer cells. This approach minimizes side effects while maximizing treatment effectiveness, making it a preferred choice for both oncologists and patients. As healthcare providers emphasize personalized treatment plans, demand for these high-performing oncology brands is expected to accelerate, further solidifying their dominance in the market.

How Are Technological Advancements Reshaping the Oncology Drug Market?

Advancements in biotechnology and genomic research are playing a pivotal role in the evolution of blockbuster oncology brands. Next-generation sequencing (NGS) and biomarker-driven drug development have enabled pharmaceutical companies to design therapies that are highly specific to individual cancer profiles. This shift toward precision oncology is leading to the creation of targeted therapies that deliver better patient outcomes while reducing toxicity and treatment resistance. Furthermore, AI-powered drug discovery is significantly shortening the time required to develop and test new oncology drugs, accelerating their path to regulatory approval. Another major technological shift in the oncology market is the rise of immunotherapies. Checkpoint inhibitors such as PD-1 and CTLA-4 inhibitors have transformed cancer treatment by harnessing the body's immune system to fight cancer. Additionally, CAR-T cell therapy has gained traction as a revolutionary approach for treating hematologic malignancies. These advancements are not only improving survival rates but also expanding treatment options for patients who previously had limited choices. As pharmaceutical companies continue investing in combination therapies that integrate immunotherapy with targeted treatments, the market for blockbuster oncology brands is poised for exponential growth.

What Market Trends Are Driving the Expansion of Blockbuster Oncology Brands?

The oncology drug market is witnessing a shift toward value-based care, where treatment effectiveness and patient-centric outcomes determine drug pricing and adoption. Governments and healthcare agencies are increasingly emphasizing the cost-effectiveness of oncology drugs, prompting pharmaceutical companies to focus on developing therapies with high clinical value. This trend has led to the expansion of outcome-based pricing models and reimbursement structures that incentivize the use of highly effective oncology brands. Another key trend shaping the market is the growing adoption of biosimilars. As patents for blockbuster oncology drugs expire, biosimilar competition is expected to intensify, driving down treatment costs and increasing accessibility for patients. However, despite biosimilar challenges, leading oncology brands continue to maintain market dominance through continuous innovation, lifecycle management strategies, and strategic partnerships with diagnostic firms to expand companion diagnostic applications. Additionally, the rise of digital health technologies, including remote patient monitoring and AI-driven treatment recommendations, is further optimizing the efficacy of blockbuster oncology therapies.

What Are the Key Growth Drivers for the Blockbuster Oncology Brands Market?

The growth in the Blockbuster Oncology Brands market is driven by several factors, including the increasing global cancer burden, continuous innovation in targeted and immunotherapies, and expanding regulatory approvals for breakthrough oncology treatments. The integration of biomarker-driven drug development is enabling pharmaceutical companies to create highly effective therapies tailored to specific cancer types, further strengthening market growth. Additionally, the rise of combination therapies, where multiple drugs work synergistically to enhance treatment efficacy, is fueling demand for blockbuster oncology brands. The growing adoption of companion diagnostics, which help identify the most suitable treatments for individual patients, is also playing a crucial role in driving market expansion. Furthermore, the shift toward personalized medicine and precision oncology, supported by advancements in genomic research and AI-powered drug discovery, is ensuring sustained growth in this segment. As investment in oncology R&D continues to rise and healthcare infrastructure improves globally, the blockbuster oncology brands market is set to witness strong and steady expansion in the coming years.

SCOPE OF STUDY:

The report analyzes the Blockbuster Oncology Brands market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Treatment Type (Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma, Other Treatment Types); Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 41 Featured) -

  • Amgen Inc.
  • Ascendis Pharma A/S
  • AstraZeneca
  • Bayer's Pharmaceuticals
  • BeiGene, Ltd.
  • Bristol-Myers Squibb Company
  • Daiichi Sankyo
  • F. Hoffmann-La Roche Ltd
  • GSK plc
  • Leapfrog Bio
  • Pfizer Inc.
  • pharmaand GmbH
  • Vidac Pharma

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Blockbuster Oncology Brands - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Global Cancer Incidence Drives Sustained Demand for High-Efficacy Oncology Therapeutics
    • Breakthrough Innovations in Immunotherapy and Targeted Therapies Propel Market Expansion of Blockbusters
    • Regulatory Accelerated Approval Pathways Strengthen Business Case for First-Mover Advantage in Oncology
    • Biopharma R&D Investment and Strategic Alliances Accelerate Drug Discovery for Novel Cancer Targets
    • Clinical Success and Overall Survival Benefit Data Propel Market Confidence in Leading Oncology Brands
    • Personalized Medicine and Biomarker-Based Therapies Expand Addressable Patient Populations
    • High Market Penetration in Developed Economies Sustains Revenue Streams for Top Oncology Brands
    • Strategic Label Expansion and New Indication Approvals Drive Lifecycle Extension of Blockbuster Drugs
    • Oncology-Focused M&A Activity Throws Spotlight on Market Consolidation and Brand Synergies
    • Digital Health and Companion Diagnostics Integration Strengthens Treatment Monitoring and Adoption
    • Intellectual Property Protection and Patent Extensions Sustain Exclusivity for Leading Brands
    • Pipeline Diversification and Portfolio Management Strategies Sustain Revenue Amidst Competitive Pressure
    • Growing Role of Real-World Evidence and Post-Market Studies Enhances Market Position of Blockbusters
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Blockbuster Oncology Brands Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Blockbuster Oncology Brands by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Lung Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Lung Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Breast Cancer by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Breast Cancer by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Multiple Myeloma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Multiple Myeloma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Lymphoma by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Lymphoma by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Other Treatment Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Other Treatment Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Distribution Channels by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Distribution Channels by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 29: USA Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: USA 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 32: USA Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: Canada 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • JAPAN
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Japan 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • CHINA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 47: China Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: China Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: China 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 50: China Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • EUROPE
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 53: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 54: Europe Historic Review for Blockbuster Oncology Brands by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Europe 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • FRANCE
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 62: France Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: France Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: France 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 65: France Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • GERMANY
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 68: Germany Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: Germany Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: Germany 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 74: Italy Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Italy Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Italy 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 80: UK Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: UK Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: UK 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 83: UK Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 86: Spain Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: Spain Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: Spain 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 92: Russia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Russia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Russia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 98: Rest of Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Rest of Europe Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Rest of Europe 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 104: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 105: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 113: Australia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Australia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Australia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • INDIA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 119: India Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: India Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: India 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 122: India Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 125: South Korea Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: South Korea Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: South Korea 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 131: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Rest of Asia-Pacific Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Rest of Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 137: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 138: Latin America Historic Review for Blockbuster Oncology Brands by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 146: Argentina Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Argentina Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Argentina 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 152: Brazil Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Brazil Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Brazil 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 158: Mexico Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Mexico Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Mexico 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 164: Rest of Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Rest of Latin America Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Rest of Latin America 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 170: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 171: Middle East Historic Review for Blockbuster Oncology Brands by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 179: Iran Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Iran Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Iran 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 185: Israel Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Israel Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Israel 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 191: Saudi Arabia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Saudi Arabia Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Saudi Arabia 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 197: UAE Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: UAE Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: UAE 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 203: Rest of Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Rest of Middle East Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Rest of Middle East 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030
  • AFRICA
    • Blockbuster Oncology Brands Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 209: Africa Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Africa Historic Review for Blockbuster Oncology Brands by Treatment Type - Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Africa 15-Year Perspective for Blockbuster Oncology Brands by Treatment Type - Percentage Breakdown of Value Sales for Lung Cancer, Breast Cancer, Multiple Myeloma, Lymphoma and Other Treatment Types for the Years 2015, 2025 & 2030
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Blockbuster Oncology Brands by Distribution Channel - Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Blockbuster Oncology Brands by Distribution Channel - Percentage Breakdown of Value Sales for Hospital Pharmacy, Retail Pharmacy and Other Distribution Channels for the Years 2015, 2025 & 2030

IV. COMPETITION

샘플 요청 목록
0 건의 상품을 선택 중
목록 보기
전체삭제